Search the Newsreel

Perceptive Advisors LLC Sells 3,106,568 Shares of Inhibikase Therapeutics, Inc. $IKT

Perceptive Advisors LLC significantly reduced its stake in Inhibikase Therapeutics (NASDAQ:IKT) by selling over 3.1 million shares, though other institutional investors like Sands Capital Alternatives and ADAR1 Capital Management increased their holdings. Despite this sale, analyst sentiment remains largely positive with an average "Buy" …

Anika Therapeutics (ANIK) Stock Fair Value Rises After Q2 Beat And Higher Guidance

Anika Therapeutics Gains 29%, Insider Trades Reap Benefit

This article reports on Anika Therapeutics' significant stock gain of 29%. The rise in stock price has benefited company insiders who engaged in recent trades.

Ilika showed commercial progress in Stereax and Goliath solid-state battery businesses - ICYMI

Ilika showed commercial progress in Stereax and Goliath solid-state battery businesses - ICYMI Proactive uses images sourced from Shutterstock Ilika PLC (AIM:IKA, OTCQX:ILIKF, FRA:I8A) this week outlined continued commercial progress across its Stereax and Goliath solid-state battery businesses, with chief executive Graeme Purdy highlighting …

Wall Street Zen Upgrades Anika Therapeutics (NASDAQ:ANIK) to Strong-Buy

Inhibikase Therapeutics, Inc. Revenue Breakdown – NASDAQ:IKT

This article provides a basic financial overview for Inhibikase Therapeutics, Inc. (NASDAQ:IKT) on TradingView. It indicates that the market is closed, with no current trades. The content primarily lists available financial data categories and links to various TradingView products and community features, rather than …

Anika Therapeutics (ANIK) Stock Jumps As Profit Returns Sharpen Margin Focus

Price to earnings forward of PT Bank Mestika Dharma Tbk – IDX:BBMD

Kritika Wires Limited Revenue Breakdown – NSE:KRITIKA

18,030,000-share swap for warrant by Inhibikase Therapeutics, Inc. (IKT)

RA Capital Healthcare Fund, L.P., a ten percent owner of Inhibikase Therapeutics, Inc. (IKT), executed an Exchange Agreement on July 29, 2026. The fund swapped 18,030,000 shares of common stock for a pre-funded warrant exercisable for the same number of shares at $0.001 per …

RA Capital group (NASDAQ: IKT) discloses 9.99% capped stake via stock and warrants

RA Capital Management, L.P., along with RA Capital Healthcare Fund, L.P., Peter Kolchinsky, and Rajeev Shah, have disclosed a beneficial ownership of 14,653,994 shares, capped at 9.99%, in Inhibikase Therapeutics, Inc. (IKT) through stock and pre-funded warrants. The pre-funded warrants include a "Beneficial Ownership …

Vanguard Capital Management (ANIK) discloses 4.95% beneficial stake in Anika Therapeutics

Vanguard Capital Management LLC has reported a 4.95% beneficial ownership stake in Anika Therapeutics Inc (ANIK), amounting to 659,216 shares as of June 30, 2026. The filing indicates that Vanguard holds sole voting power over 87,103 shares and sole dispositive power over all 659,216 …

H.C. Wainwright reiterates Inhibikase stock rating on FDA orphan drug status

H.C. Wainwright has reiterated a Buy rating and an $8.00 price target for Inhibikase Therapeutics Inc (NASDAQ:IKT) after the company received FDA Orphan Drug Designation for IKT-001, its lead product candidate for pulmonary arterial hypertension. This designation provides significant incentives and potential market exclusivity. …

PT Mora Telematika Indonesia Tbk Reports Earnings Results for the Half Year Ended June 30, 2026

Kritika Wires Ltd. Share Price Soars 13.16% Today

B. Riley Adjusts Anika Therapeutics Price Target to $21 From $18, Maintains Buy Rating

B. Riley has increased its price target for Anika Therapeutics (ANIK) to $21 from $18, while reaffirming its Buy rating on the stock. This adjustment reflects a positive outlook on the company, concurrent with Barrington also raising its price target to $21 and maintaining …

Is Playtika (PLTK) Outperforming Other Consumer Discretionary Stocks This Year?

Investors interested in Consumer Discretionary stocks should always be looking to find the best-performing companies in the group. Playtika Holding (PLTK) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as …

Inhibikase Therapeutics Inc (IKT) Financial Health: Profitability & Balance Sheet Analysis

This article provides an analysis of Inhibikase Therapeutics Inc's (IKT) financial health, ranking it 237 out of 384 in the Biotechnology & Medical Research industry. The company's financial status is described as robust, but its operating efficiency is low. Key financial metrics such as …

Hikal Q1 FY27 Earnings Call Scheduled for August 6 at 5 PM IST

CZR: Recommended Zuleika Gold takeover, strong $65.1M cash, and high-grade Croydon results

Playtika (PLTK) to Release Quarterly Earnings on Thursday

Anika Therapeutics Inc (ANIK) Q2 2026 Earnings Call Highlights: Record Revenue and Margin ...

Anika Therapeutics Inc (ANIK) reported record Q2 2026 results, including a 17% increase in commercial channel revenue, a 65% gross margin, and record international revenue of $12.6 million. Adjusted EBITDA reached $7.1 million, and the company raised its full-year 2026 guidance. Despite these positive …

Anika Therapeutics 2Q Adj EPS 42c >ANIK

This article reports that Anika Therapeutics' adjusted earnings per share (EPS) for the second quarter were 42 cents. The headline provides the key financial performance indicator for the company.

Press Release: Anika Reports Second Quarter 2026 Financial Results

This press release from Anika reports their second quarter 2026 financial results. The document (although not provided) would contain key financial metrics and performance highlights for the period, offering insight into the company's fiscal health and operational achievements.

Playtika Holding Corp (PLTK) Financial Health: Profitability & Balance Sheet Analysis

The article provides a financial health analysis of Playtika Holding Corp (PLTK), noting its current financial score of 6.90 and stable financial status with average operating efficiency. It highlights a year-over-year revenue increase of 5.48% and a significant net profit increase of 287.91%. The …

Anika Therapeutics Releases Q2 2026 Financial Results

Anika Therapeutics, Inc. reported a significant turnaround in Q2 2026, with adjusted earnings of $0.42 per share, exceeding expectations by 625.0%. The company's revenue increased by 16.0% to $32.6M, driven by strong growth in both its Commercial and OEM channels. This return to profitability …

Anika Therapeutics Q2 2026 slides: margins surge, guidance raised

Anika Therapeutics reported Q2 2026 results that significantly exceeded analyst expectations, with adjusted earnings of $0.42 per share and revenue of $32.6 million. The company's shares surged on the news, driven by a successful operational transformation leading to expanded gross margins of 65% and …

Anika Therapeutics Q2 2026: Revenue $32.6M, Gross Margin 65%, Net Income $3.3M

Anika Therapeutics reported strong Q2 2026 results, with revenue reaching $32.6 million, a 16% year-over-year increase, and a gross margin of 65%. The company achieved a net income of $3.3 million and adjusted diluted EPS of $0.42. Management raised its full-year 2026 revenue and …

Anika: Q2 Earnings Snapshot

This article provides a second-quarter earnings snapshot for Anika. It contains no financial details or further information about the company's performance. The article is exceptionally brief, offering only a title without substantive content.

Anika Therapeutics Q2 revenue rises, lifts 2026 outlook

Anika Therapeutics reported a rise in its second-quarter revenue, leading the company to subsequently lift its financial outlook for 2026. This positive performance and improved forecast were highlighted in a Reuters news brief accessible via TradingView.

ERIKA CARMEL-TECH LTD Revenue Breakdown – TASE:ERKA

ADAR1 Capital Management LLC Reduces Stock Position in Inhibikase Therapeutics, Inc. $IKT

ADAR1 Capital Management LLC significantly reduced its stake in Inhibikase Therapeutics (NASDAQ:IKT) by 18.1% in the first quarter, selling over 1.4 million shares. Despite this reduction, other institutional investors like BNP Paribas Financial Markets, Barclays PLC, and Virtu Financial LLC increased their positions. The …

Anika Therapeutics (NASDAQ:ANIK) Releases Quarterly Earnings Results, Beats Estimates By $0.27 EPS

Anika Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:ANIK) 2026-07-29

Stocks to Watch Today: Graphite India, Rail Vikas Nigam, Larsen and Toubro, Birlasoft, Tata Capital,...

Crete Plastics SA Revenue Breakdown – ATHEX:PLAKR